SAADI Fatima-Zahra* and ABDAOUI Abderrahmane
Hydroxychloroquine (HCQ) is an analogue of chloroquine, with fewer side effects. This antimalarial was proposed in the early phase of COVID-19 pandemic as a potential treatment. HCQ is an old drug used for several chronic diseases such as systemic lupus replication in a concentration-dependent manner. It has been confirmed that HCQ effectively inhibits the entry step and the postentry stages of SARS-CoV-2. It also suggested that HCQ blocked the transport of SARS-CoV-2 from endosomes to endolysosomes, which is essential to release the viral genome as in the case of SARS-CoV-2. But it prescription in COVID-19 disease garnered exceptional interest. For that, many studies were carried all over the word to assess its efficiency compared to standard care. The current paper is a quick view on the main discussion corners about HCQ in COVID-19 disease.
Results of in vitro researches stimulate retrospective and observational studies. Findings concerning the efficiency were inconsistent between these studies, which require clinical trials. A lot of randomized controlled trials were conducted then, but conclusions were opposite. The optimal dose regimens and the need for HCQ monitoring also constitute a point of discord between these studies.
